Lactobacillus rhamnosus GG

The Microbiota in Gastrointestinal Pathophysiology: Implications for Human Health, Prebiotics, Probiotics, and Dysbiosis

Volumn , Issue , 2017, Pages 79-88

  Gorbach, S ^a,b   Doron, S ^a,b   Magro, F ^a,b  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TUFTS MEDICAL CENTER   (United States)

Author keywords

Antibiotic associated diarrhea; Diarrhea; Lactobacillus GG; Lactobacillus rhamnosus GG; LGG; Probiotics

Indexed keywords

EID: 85027305038     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-804024-9.00007-0     Document Type: Chapter

References (80)

1. Segers M., Lebeer S. Towards a better understanding of Lactobacillus rhamnosus GG-host interactions. Microb Cell Fact 2014, 13:S7.
2. Doron S., Snydman D.R., Gorbach S.L. Lactobacillus GG: bacteriology and clinical applications. Gastroenterol Clin North Am 2005, 34(3):483-498.
3. Silva M., Jacobus N.V., Deneke C., et al. Antimicrobial substance from a human Lactobacillus strain. Antimicrob Agents Chemother 1987, 31(8):1231-1233.
4. Kankainen M., Paulin L., Tynkkynen S., et al. Comparative genomic analysis of Lactobacillus rhamnosus GG reveals pili containing a human-mucus binding protein. Proc Natl Acad Sci 2009, 106(40):17193-17198.
5. Marianelli C., Cifani N., Pasquali P. Evaluation of antimicrobial activity of probiotic bacteria against Salmonella enterica subsp. enterica serovar typhimurium 1344 in a common medium under different environmental conditions. Res Microbiol 2010, 161:673-680.
6. Lu R., Fasano S., Madayiputhiya N., et al. Isolation, identification, and characterization of small bioactive peptides from Lactobacillus GG conditional media that exert both anti-Gram-negative and Gram-positive bactericidal activity. J Pediatr Gastroenterol Nutr 2009, 49:23-30.
7. De Keersmaecker S.C.J., Verhoeven T.L.A., Desair J., et al. Strong antimicrobial activity of Lactobacillus rhamnosus GG against Salmonella typhimurium is due to accumulation of lactic acid. FEMS Microbiol Lett. 2006, 259(1):89-96.
8. Manome A., Okada S., Uchimura T., et al. The ratio of l-form to d-form of lactic acid as a criteria for the identification of lactic acid bacteria. J Gen Appl Microbiol 1998, 44(6):371-374.
9. Goldin B.R., Gorbach S.L., Saxelin M., et al. Survival of Lactobacillus species (strain GG) in human gastrointestinal tract. Dig Dis Sci 1992, 37(1):121-128.
10. Salminen M.K., Rautelin H., Tynkkynen S., et al. Lactobacillus bacteremia, species identification, and antimicrobial susceptibility of 85 blood isolates. Clin Infect Dis 2006, 42(5):e35-e44.
11. Krishnan V. Pilins in Gram-positive bacteria: a structural perspective. IUBMB Life 2015, 67(7):533-543.
12. Tripathi P., Dupres V., Beaussart A., et al. Deciphering the nanometer-scale organization and assembly of Lactobacillus rhamnosus GG pili using atomic force microscopy. Langmuir 2012, 28(4):2211.
13. Reunanen J., von Ossowski I., Hendrickx A.P.A., et al. Characterization of the SpaCBA pilus fibers in the probiotic Lactobacillus rhamnosus GG. Appl Environ Microbiol 2012, 78(7):2337-2344.
14. Tripathi P., Beaussart A., Alsteens D., et al. Adhesion and nanomechanics of pili from the probiotic Lactobacillus rhamnosus GG. ACS Nano 2013, 7(4):3685-3697.
15. Meurman J.H., Antila H., Salminen S. Recovery of Lactobacillus strain GG (ATCC 53103) from saliva of healthy volunteers after consumption of yoghurt prepared with the bacterium. Microb Ecol Health Dis 1994, 7(6):295-298.
16. Alander M., Satokari R., Korpela R., et al. Persistence of colonization of human colonic mucosa by a probiotic strain, Lactobacillus rhamnosus GG, after oral consumption. Appl Environ Microbiol 1999, 65(1):351-354.
17. Lebeer S., Claes I.J., Verhoeven T.L., et al. Exopolysaccharides of Lactobacillus rhamnosus GG form a protective shield against innate immune factors in the intestine. Microb Biotechnol 2011, 4:368-374.
18. Yan F., Polk D.B. Probiotic bacterium prevents cytokine-induced apoptosis in intestinal epithelial cells. J Biol Chem 2002, 277:50959-50965.
19. Tao Y., Drabik K.A., Waypa T.S., et al. Soluble factors from Lactobacillus GG activate MAPKs and induce cytoprotective heat shock proteins in intestinal epithelial cells. Am J Physiol 2006, 290:C1018-C1030.
20. Yan F., Cao H., Cover T.L., et al. Soluble proteins produced by probiotic bacteria regulate intestinal epithelial cell survival and growth. Gastroenterology 2007, 132:562-575.
21. Seth A., Yan F., Polk D.B., et al. Probiotics ameliorate the hydrogen peroxide-induced epithelial barrier disruption by a PKC- and MAP kinase-dependent mechanism. Am J Physiol 2008, 294:G1060-G1069.
22. Wilson K.H., Perini F. Role of competition for nutrients in suppression of Clostridium difficile by the colonic microflora. Infect Immun 1988, 56(10):2610-2614.
23. Di Caro S., Tao H., Grillo A., et al. Effects of Lactobacillus GG on genes expression pattern in small bowel mucosa. Dig Liver Dis 2005, 37:320-329.
24. Eloe-Fadrosh E.A., Brady A., Crabtree J., et al. Functional dynamics of the gut microbiome in elderly people during probiotic consumption. MBio 2015, 6(2):1-119.
25. Hamer H.M., Jonkers D., Venema K., et al. Review article: the role of butyrate on colonic function. Aliment Pharmacol Ther 2008, 27(2):104-119.
26. Luhrs H., Kudlich T., Neumann M., et al. Butyrate-enhanced TNFalpha-induced apoptosis is associated with inhibition of NF-kappaB. Anticancer Res 2002, 22(3):1561-1568.
27. Bajaj J., Heuman D., Hylemon P., et al. Randomised clinical trial: Lactobacillus GG modulates gut microbiome, metabolome and endotoxemia in patients with cirrhosis. Aliment Pharmacol Ther 2014, 39(10):1113-1125.
28. Bruzzese E., Callegari M.L., Raia V., et al. Disrupted intestinal microbiota and intestinal inflammation in children with cystic fibrosis and its restoration with Lactobacillus GG: a randomised clinical trial. PLoS One 2014, 9(2):e87796.
29. Hempel S., Newberry S., Ruelaz A., et al. Safety of probiotics used to reduce risk and prevent or treat disease. Evid Rep Technol Assess (Full Rep). 2011, 200:1-645.
30. Joint FAO/WHO. WHO Working Group on Drafting Guidelines for the Evaluation of Probiotics in Food. Guidelines for the evaluation of probiotics in food: report of a Joint FAO/WHO Working Group on Drafting Guidelines for the Evaluation of Probiotics in Food. London (ON, Canada), April 30 and May 1. Available from:; 2002. ftp://ftp.fao.org/es/esn/food/wgreport2.pdf.
31. Ouwehand A.C., Saxelin M., Salminen S. Phenotypic differences between commercial Lactobacillus rhamnosus GG and L. rhamnosus strains recovered from blood. Clin Infect Dis 2004, 39(12):1858-1860.
32. Doron S., Snydman D.R. Risk and safety of probiotics. Clin Infect Dis 2015, 60(Suppl. 2):S129-S134.
33. Munakata S., Arakawa C., Kohira R., et al. A case of d-lactic acid encephalopathy associated with use of probiotics. Brain Dev 2010, 32(8):691-694.
34. Ku W., Lau D., Huen K. Other articles probiotics provoked d-lactic acidosis in short bowel syndrome: case report and literature review. HK J Paediatr 2006, 11(3):246-254.
35. Oh M.S., Phelps K.R., Traube M., et al. d-lactic acidosis in a man with the short-bowel syndrome. N Engl J Med 1979, 301(5):249-252.
36. Veckman V., Miettinen M., Pirhonen J., et al. Streptococcus pyogenes and Lactobacillus rhamnosus differentially induce maturation and production of Th1-type cytokines and chemokines in human monocyte-derived dendritic cells. J Leukoc Biol 2004, 75(5):764-771.
37. Tynkkynen S., Singh K.V., Varmanen P. Vancomycin resistance factor of Lactobacillus rhamnosus GG in relation to enterococcal vancomycin resistance (van) genes. Int J Food Microbiol 1998, 41(3):195-204.
38. Turck D., Bernet J., Marx J., et al. Incidence and risk factors of oral antibiotic-associated diarrhea in an outpatient pediatric population. J Pediatr Gastroenterol Nutr 2003, 37(1):22-26.
39. Kotowska M., Albrecht P., Szajewska H. Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea in children: a randomized double-blind placebo-controlled trial. Aliment Pharmacol Ther 2005, 21(5):583-590.
40. Wenus C., Goll R., Loken E., et al. Prevention of antibiotic-associated diarrhoea by a fermented probiotic milk drink. Eur J Clin Nutr 2008, 62(2):299-301.
41. Vanderhoof J.A., Whitney D.B., Antonson D.L., et al. Lactobacillus GG in the prevention of antibiotic-associated diarrhea in children. J Pediatr 1999, 135(5):564-568.
42. Arvola T., Laiho K., Torkkeli S., et al. Prophylactic Lactobacillus GG reduces antibiotic-associated diarrhea in children with respiratory infections: a randomized study. Pediatrics 1999, 104(5):e64.
43. Szajewska H., Kotowska M., Mrukowicz J.Z., et al. Efficacy of Lactobacillus GG in prevention of nosocomial diarrhea in infants. J Pediatr 2001, 138(3):361-365.
44. Thomas M., Litin S., Osmon D., et al. Lack of effect of Lactobacillus GG on antibiotic-associated diarrhea: a randomized, placebo-controlled trial. Mayo Clin Proc 2001, 76(9):883-889.
45. Armuzzi A., Cremonini F., Ojetti V., et al. Effect of Lactobacillus GG supplementation on antibiotic-associated gastrointestinal side effects during Helicobacter pylori eradication therapy: a pilot study. Digestion 2001, 63(1):1-7.
46. Armuzzi A., Cremonini F., Bartolozzi F., et al. The effect of oral administration of Lactobacillus GG on antibiotic-associated gastrointestinal side-effects during Helicobacter pylori eradication therapy. Aliment Pharmacol Ther 2001, 15(2):163-169.
47. Cremonini F., Di Caro S., Covino M., et al. Effect of different probiotic preparations on anti-Helicobacter pylori therapy-related side effects: a parallel group, triple blind, placebo-controlled study. Am J Gastroenterol 2002, 97(11):2744-2749.
48. Fox M.J., Ahuja K.D., Robertson I.K., et al. Can probiotic yogurt prevent diarrhoea in children on antibiotics? A double-blind, randomised, placebo-controlled study. BMJ Open 2015, 5(1):e006474.
49. Szajewska H., Kołodziej M. Systematic review with meta-analysis: Lactobacillus rhamnosus GG in the prevention of antibiotic-associated diarrhoea in children and adults. Aliment Pharmacol Ther 2015, 42(10):1149-1157.
50. Doron S.I., Hibberd P.L., Gorbach S.L. Probiotics for prevention of antibiotic-associated diarrhea. J Clin Gastroenterol 2008, 42(Suppl. 2):S58-S63.
51. Basu S., Paul D.K., Ganguly S., et al. Efficacy of high-dose Lactobacillus rhamnosus GG in controlling acute watery diarrhea in Indian children: a randomized controlled trial. J Clin Gastroenterol 2009, 43(3):208-213.
52. Szajewska H., Mrukowicz J.Z. Probiotics in the treatment and prevention of acute infectious diarrhea in infants and children: a systematic review of published randomized, double-blind, placebo-controlled trials. J Pediatr Gastroenterol Nutr 2001, 33:S17-S25.
53. Huang J.S., Bousvaros A., Lee J.W., et al. Efficacy of probiotic use in acute diarrhea in children: a meta-analysis. Dig Dis Sci 2002, 47(11):2625-2634.
54. Sindhu K.N., Sowmyanarayanan T.V., Paul A., et al. Immune response and intestinal permeability in children with acute gastroenteritis treated with Lactobacillus rhamnosus GG: a randomized, double-blind, placebo-controlled trial. Clin Infect Dis 2014, 58(8):1107-1115.
55. Pochapin M. The effect of probiotics on Clostridium difficile diarrhea. Am J Gastroenterol 2000, 95(1):S11-S13.
56. Gorbach S., Chang T., Goldin B. Successful treatment of relapsing Clostridium difficile colitis with Lactobacillus GG. Lancet 1987, 330(8574):1519.
57. Biller J., Katz A., Flores A., et al. Treatment of recurrent Clostridium difficile colitis with Lactobacillus GG. J Pediatr Gastroenterol Nutr 1995, 21(2):224-226.
58. Bennett R.G., Gorbach S.L., Goldin B.R., et al. Treatment of relapsing Clostridium difficile diarrhea with Lactobacillus GG. Nutr Today 1996, 31(6):39S.
59. DiBaise J.K., Zhang H., Crowell M.D., et al. Gut microbiota and its possible relationship with obesity. Mayo Clin Proc 2008, 83(4):460-469.
60. Gionchetti P., Rizzello F., Venturi A., et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 2000, 119(2):305-309.
61. Ley R.E., Backhed F., Turnbaugh P., et al. Obesity alters gut microbial ecology. Proc Natl Acad Sci USA 2005, 102(31):11070-11075.
62. Ley R.E., Turnbaugh P.J., Klein S., et al. Microbial ecology: human gut microbes associated with obesity. Nature 2006, 444(7122):1022-1023.
63. Turnbaugh P.J., Bäckhed F., Fulton L., et al. Diet-induced obesity is linked to marked but reversible alterations in the mouse distal gut microbiome. Cell Host Microbe 2008, 3(4):213-223.
64. Turnbaugh P.J., Ley R.E., Mahowald M.A., et al. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006, 444(7122):1027-1131.
65. Ji Y., Kim H., Park H., et al. Modulation of the murine microbiome with a concomitant anti-obesity effect by Lactobacillus rhamnosus GG and Lactobacillus sakei NR28. Benef Microbes 2012, 3(1):13-22.
66. Horton J.D., Goldstein J.L., Brown M.S. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 2002, 109(9):1125-1132.
67. Tappy L., Le K.A. Metabolic effects of fructose and the worldwide increase in obesity. Physiol Rev 2010, 90(1):23-46.
68. Luoto R., Kalliomäki M., Laitinen K., et al. The impact of perinatal probiotic intervention on the development of overweight and obesity: follow-up study from birth to 10 years. Int J Obes 2010, 34(10):1531-1537.
69. Hojsak I., Snovak N., Abdovic S., et al. Lactobacillus GG in the prevention of gastrointestinal and respiratory tract infections in children who attend day care centers: a randomized, double-blind, placebo-controlled trial. Clin Nutr 2015, 29(3):312-316.
70. Morrow L.E., Kollef M.H., Casale T.B. Probiotic prophylaxis of ventilator-associated pneumonia: a blinded, randomized, controlled trial. Am J Respir Crit Care Med 2010, 182:1058-1064.
71. Yasui H., Kiyoshima J., Hori T. Reduction of influenza virus titer and protection against influenza virus infection in infant mice fed Lactobacillus casei Shirota. Clin Diagn Lab Immunol 2004, 11(4):675-679.
72. Davidson L.E., Fiorino A., Snydman D.R., et al. Lactobacillus GG as an immune adjuvant for live-attenuated influenza vaccine in healthy adults: a randomized double-blind placebo-controlled trial. Eur J Clin Nutr 2011, 65(4):501-507.
73. Wu C., Chen P., Lee Y., et al. Effects of immunomodulatory supplementation with Lactobacillus rhamnosus on airway inflammation in a mouse asthma model. J Microbiol Immunol Infect 2014.
74. Isolauri E., Majamaa H., Arvola T., et al. Lactobacillus casei strain GG reverses increased intestinal permeability induced by cow milk in suckling rats. Gastroenterology 1993, 105(6):1643-1650.
75. Kalliomaki M., Salminen S., Poussa T., et al. Probiotics and prevention of atopic disease: 4-year follow-up of a randomised placebo-controlled trial. Lancet 2003, 361:1869-1871.
76. Isolauri E., Arvola T., Sutas Y., et al. Probiotics in the management of atopic eczema. Clin Exp Allergy 2000, 30(11):1604-1610.
77. Nermes M., Kantele J.M., Atosuo T.J., et al. Interaction of orally administered Lactobacillus rhamnosus GG with skin and gut microbiota and humoral immunity in infants with atopic dermatitis. Clin Exp Allergy 2011, 41(3):370-377.
78. Baldassarre M.E., Laforgia N., Fanelli M., et al. Lactobacillus GG improves recovery in infants with blood in the stools and presumptive allergic colitis compared with extensively hydrolyzed formula alone. J Pediatr 2010, 156(3):397-401.
79. Pärtty A., Lehtonen L., Kalliomäki M., et al. Probiotic Lactobacillus rhamnosus GG therapy and microbiological programming in infantile colic: a randomized, controlled trial. Pediatr Res 2015, 78(4):470-475.
80. Francavilla R., Miniello V., Magista A.M., et al. A randomized controlled trial of Lactobacillus GG in children with functional abdominal pain. Pediatrics 2010, 126(6):e1445-e1452.